Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley J, Sanchez Y, Penrod J, Goldman D, et al. Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.1301

Reference

Title
Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley J, Sanchez Y, Penrod J, Goldman D, et al.
Volume & Issue
Volume 31, Issue 4
Pages
683-690
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Investments in cancer research and development between 1998 and 2000 has generated 23 million additional healthy years of life and $1.9 trillion of additional social value.  
  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
  • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…  
  • Medicines in Development for Cancer